Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 20Pancreatic Neoplasms 19Carcinoma, Non-Small-Cell Lung 17Ovarian Neoplasms 16Fallopian Tube Neoplasms 12Triple Negative Breast Neoplasms 10Neoplasm Metastasis 10Carcinoma, Ovarian Epithelial 10Unspecified Adult Solid Tumor, Protocol Specific 8Neoplasms 7Lung Neoplasms 7Endometrial Neoplasms 7Esophageal Neoplasms 6Brenner Tumor 6Breast Neoplasms, Male 6Stomach Neoplasms 5Melanoma 5Squamous Cell Carcinoma of Head and Neck 4Peritoneal Neoplasms 3Gallbladder Neoplasms 3Cholangiocarcinoma 3Adenocarcinoma of Lung 3Adenocarcinoma 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Salivary Gland Neoplasms 2Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Non-Hodgkin 2Leukemia, Lymphocytic, Chronic, B-Cell 2

Interventions

palbociclib 1defactinib 1adavosertib 1Taxes 1Radiation 1RO5126766 1Platinum 1Paclitaxel 1Fulvestrant 1Dasatinib 1Congresses as Topic 1Cisplatin 1Carboplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Carcinoma, Endometrioid × Taxes × Clear all
NCT01440998 2018-04-05

Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer

National Cancer Institute (NCI)

Phase 1 Completed
18 enrolled

Carcinoma, Endometrioid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡